Similar articles

• Leuprolide for prostate cancer.

  [No authors listed] [No authors listed] Med Lett Drugs Ther. 1985 Aug 16;27(694):71-2. Med Lett Drugs Ther. 1985. PMID: 2410765 Clinical Trial. No abstract available.
• Effect of leuprolide and cetrorelix on cell growth, apoptosis, and GnRH receptor expression in primary cell cultures from human prostate carcinoma.

  Castellón E, Clementi M, Hitschfeld C, Sánchez C, Benítez D, Sáenz L, Contreras H, Huidobro C. Castellón E, et al. Cancer Invest. 2006 Apr-May;24(3):261-8. doi: 10.1080/07357900600629591. Cancer Invest. 2006. PMID: 16809153
• The efficacy and safety of degarelix: a 12-month, comparative, randomized, open-label, parallel-group phase III study in patients with prostate cancer.

  Klotz L, Boccon-Gibod L, Shore ND, Andreou C, Persson BE, Cantor P, Jensen JK, Olesen TK, Schröder FH. Klotz L, et al. BJU Int. 2008 Dec;102(11):1531-8. doi: 10.1111/j.1464-410X.2008.08183.x. BJU Int. 2008. PMID: 19035858 Clinical Trial.
• Leuprolide with flutamide for complete androgen ablation: therapeutic alternative for advanced prostatic cancer (stage D2).

  Chime-Udeh E. Chime-Udeh E. Conn Med. 1991 Sep;55(9):526-8. Conn Med. 1991. PMID: 1748007 Review. No abstract available.
• Expert opinion on 6-monthly luteinizing hormone-releasing hormone agonist treatment with the single-sphere depot system for prostate cancer.

  Schulman C, Alcaraz A, Berges R, Montorsi F, Teillac P, Tombal B. Schulman C, et al. BJU Int. 2007 Jul;100 Suppl 1:1-5. doi: 10.1111/j.1464-410X.2007.06967.x. BJU Int. 2007. PMID: 17593201 Review. No abstract available.